Product image of Opzelura (Ruxolitinib) supplied by GNH India

Opzelura

Active Ingredient:
Ruxolitinib
Origin:
EU

Opzelura (Ruxolitinib)

Ruxolitinib, the active ingredient in Opzelura, is a Janus kinase (JAK) inhibitor presented as a 1.5% w/w cream for topical use. It treats atopic dermatitis in patients who need a non‑systemic option or have not responded adequately to conventional therapies.

GNH India supplies Opzelura as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Incyte Biosciences Distribution B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Opzelura (ruxolitinib) is a topical Janus kinase inhibitor indicated for inflammatory skin conditions.
  • Adult atopic dermatitis: improves skin lesions and reduces itch in adults with moderate to severe disease.
  • Pediatric atopic dermatitis: provides similar benefits in children aged 12 years and older with moderate to severe disease.
  • Inadequate response to topical corticosteroids: offers an alternative topical therapy to control inflammation when steroids are insufficient.

How It Works

  • Ruxolitinib selectively inhibits Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) enzymes, blocking downstream STAT signaling pathways that mediate cytokine‑driven inflammation. By reducing the activity of pro‑inflammatory cytokines such as IL‑4, IL‑13, and IFN‑γ in the skin, the cream diminishes inflammatory cell recruitment and keratinocyte activation, leading to clinical improvement of dermatitis.

Side Effects

Common Side Effects

  • Application site irritation: redness, burning, or stinging at the site of cream application.
  • Pruritus: transient itching that may occur shortly after use.
  • Dryness or scaling of the treated skin.
  • Erythema: mild redness of the skin.
  • Folliculitis: inflammation of hair follicles.
  • Contact dermatitis: allergic skin reaction to the formulation.

Serious or Rare Side Effects

  • Skin infection: bacterial, viral, or fungal infection of the treated area.
  • Severe allergic reaction: angioedema or anaphylaxis requiring immediate medical attention.
  • Disseminated herpes simplex or zoster infections.
  • Malignancy: rare reports of skin cancers with prolonged immunosuppression.
  • Systemic immunosuppression: potential for increased susceptibility to opportunistic infections.

Precautions & Warnings

Before using Opzelura, consider the following precautions:

  • Avoid use on infected or broken skin: may worsen infection.
  • Do not apply to areas with active eczema herpeticum: risk of viral spread.
  • Monitor for signs of infection: redness, swelling, or pus formation.
  • Limit application to prescribed body surface area: excessive use can increase systemic exposure.
  • Pregnancy and lactation: safety unknown; discuss risks with a healthcare professional.
  • Store at room temperature below 25°C: keep in the original container, protect from moisture and light.

Avoid Interactions

Opzelura may interact with other agents that affect immune function.

Major Interactions (Avoid)

  • Concomitant systemic immunosuppressants (e.g., methotrexate, cyclosporine): additive risk of infection.
  • Use with other topical JAK inhibitors: excessive local immunosuppression.

Moderate Interactions (Monitor Closely)

  • Topical corticosteroids: may increase local immunosuppressive effect.
  • Antifungal creams (e.g., azoles): potential reduction in antifungal efficacy.
  • Live vaccines: may diminish vaccine response; consider timing of vaccination.

Frequently Asked Questions

Opzelura is a prescription topical cream containing ruxolitinib, a Janus kinase inhibitor. It is approved for the treatment of moderate to severe atopic dermatitis in patients who need an alternative to or have not responded adequately to conventional topical therapies.

Ruxolitinib blocks the activity of JAK1 and JAK2 enzymes in skin cells, which interrupts cytokine signaling pathways that drive inflammation. By reducing the release of inflammatory mediators such as interleukins and interferon‑γ, the cream helps to calm skin inflammation and relieve itching.

The specific amount and frequency of Opzelura are determined by the prescribing healthcare professional based on the severity of the dermatitis, the area of skin involved, and patient age. Patients should follow the prescriber’s instructions and not alter the dosing regimen on their own.

The safety of Opzelura in pregnancy and lactation has not been established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using this medication.

To request Opzelura, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements) and the necessary import documentation.

Compared with topical corticosteroids, Opzelura offers a non‑steroidal option that targets specific inflammatory pathways, potentially reducing steroid‑related side effects. Unlike systemic JAK inhibitors, the topical formulation limits systemic exposure while still providing effective control of skin inflammation.

Opzelura should be stored at room temperature below 25 °C. Keep the cream in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use.

The cream is applied thinly to clean, dry skin on the affected areas, typically once or twice daily as directed by the prescriber. Hands should be washed before and after application, and the treated skin should be allowed to dry before covering with clothing.

Serious risks include skin infections (bacterial, viral, or fungal) and rare severe allergic reactions such as angioedema or anaphylaxis. Patients should seek immediate medical attention if they notice signs of infection, widespread rash, swelling, or difficulty breathing.

Opzelura is contraindicated in individuals with known hypersensitivity to ruxolitinib or any component of the cream. It should also be avoided on skin that is actively infected, ulcerated, or has herpes simplex lesions, and it is not recommended for use in pregnant or nursing women without medical advice.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ruxolitinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT